Crovalimab

Phase 3

Roche Holding AG (RHHBY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Development History

Aug '26

RHHBYPhase 2$316.4B

✓Completed

Crovalimab Phase 2 Est. Readout

Crovalimab• Atypical Hemolytic Uremic Syndrome59

Aug 2026~Confirmed

CT.gov

Competitive Landscape

0 competitors in Atypical Hemolytic Uremic Syndrome

View Full Landscape

Drug Information

Target Indication

Atypical Hemolytic Uremic Syndrome

Clinical Trial

NCT04861259

Last updated: 1/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/22/2024

Piasky

Piasky as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): In patients with haemolysis with clinical symptom(s) indicative of high disease activity. In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Biotechnology•Europe•NYSE

Related Pipeline

RO7204239Phase 3

Obesity

trastuzumab (Herceptin®)Phase 3

Breast Cancer